Five Prime Therapeutics Unveils Phase 1 Data

Five Prime Therapeutics said on Saturday that it presented data from a phase 1 trial of FPA 144 for the treatment of gastric cancer, as well as for cabralizumab in patients with pigmented villonodular synovitis (PVNS) at the American Society of Clinical Oncology Annual Meeting in Chicago. Part 2 of the ongoing phase 1 trial of FPA 144 is evaluating the safety, pharmacokinetics and efficacy of biweekly infusions of FPA144 in gastric cancer patients whose tumors overexpress fibroblast growth factor receptor 2b (FGFR2b). FPA144 monotherapy demonstrated early evidence of anti-tumor efficacy in heavily pretreated patients, the company said.

The company also presented initial clinical data from the ongoing phase 1/2 trial of cabiralizumab in patients with PVNS. Results indicate cabiralizumab is shown to reduce tumor size, as well as improvements in pain and functional status.